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without prevention therapy revealed a significant (p<0,05) reduction of BMD (LS -1,9%, 
FN -4,1%) and z-score (LS -1,5%, FN -3,6%) within 12 months. The fracture incidence 
was 6%. LS-BMD loss correlated negatively (r=-0,7; p<0,01) with the increase in iPTH 
and iPTH correlated positively with craatinine (r=0,51; p<0,05). Pts. with calcium supple- 
mentation demonstrated also a 6% fracture incidence and a decrease in BMD (LS -0,9%, 
FN -1,2%) as well as z-score (LS -0,9%, FN -0,9%) which was not statistically significant. 
BMD and z-score were not significant different between both groups. Conclusions: Pts. 
with CHF demonstrate a progressive decrease in BMD in comparison to age-matched 
healthy individuals. Increased bone resorption due to a secondary hyperparathyroidism 
is a frequent reason for this BMD loss. Calcium supplementation alone can not suffi- 
ciently prevent the decrease in BMD. Depending of the individual BMD-status an addi- 
tional therapy with vitamin D and / or bisphosphonates should be recommended for pts. 
with CHF. 
1134-147 Ef fects  of  Neslr l t lde (B-Type Natr iuret ic  Peptide) on 
Pulmonary Artery Pressures In Pat ients  With Acute 
Decompenseted Congestive Heart Failure 
James B. Youno. The Cleveland Clinic Foundation, Section of Heart Failure and Cardiac 
Transplant Medicine, Cleveland, Ohio. 
Baekoround: The rapid end significant reductions in pulmonary capillary wedge pres- 
sure and dyspnea with the use of nesiritide in patients with acutely decompensated con- 
gestive heart failure (CHF) have been previously described. Because patients with CHF 
frequently have concomitant pulmonary hypertension, the effects of nesiritide and intra- 
venous nitroglycerin (IV NTG) on pulmonary pressures were explored in a large, random- 
ized, controlled trial (Vasodilation in the Management of Acute CHF - VMAC) that 
enrolled patients with acutely decompensatad CHF and NYHA class IV symptoms on 
presentation. 
Mothods: In VMAC, the randomization was stratified based on investigator decision to 
use a pulmonary artery catheter for patient management or not. Hospitalized patients 
with acutely decompensetad CHF were randomized to nesidtide (n=124), placebo 
(n=62), or IV NTG (n=60). 
Ruults:  Mean pulmonary artery systolic (PAS) and diastolic (PAD) pressures were ele- 
vated at baseline (59.2 + 12.9 and 28.4 + 7.09 mmHg, respectively), but were compara- 
ble in the 3 treatment arms. Nssiritide was superior to placebo at all time points and to IV 
NTG at most time points at reducing PAS and PAD (see figure). 
Conclusion: Nesiritide, but not IV NTG, effectively and rapidly reduces pulmonary pres- 
sures compared to placebo. In patients with acute CHF end elevated pulmonary pres- 
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1134-148 Does Digitalis Influence the Response to Beta-Blockade 
in Patients With Severe Chronic Heart Failure? Results 
of the COPERNICUS Study 
Alan B. Miller. Chdstopher O'Connor, Andrew J. Coats, Henry Krum, Michel Tendera, 
Paul Mohasci, Jean L. Rouleau, Michael B. Fowler, Hugo A. Katus, Ellen B. Roecker, 
Milton Packer, for the COPERNICUS Study Group, University of Florida, Jacksonville, 
Florida. 
Background. Most trials demonstrating the efficacy of J]-blockers (~B) in chronic heart 
failure (HF) enrolled patients receiving digitalis (DIG). Thus, little is known about the effi- 
cacy and safety of !3B in patients who are not digitalized. Like I~B, DIG may attenuate the 
effects of the sympathetic nervous system, but unlike ~B, DIG exerts positive inotropic 
effects that may be valuable in ~-btocked patients. 
Methods. To evaluate this possibility, we assessed the effects of carvedilol (CRV) vs pla- 
cebo (PBO) in patients with severe HF enrolled in the COPERNICUS study. Of the 2289 
patients in the trial, 1513 were receiving DIG (PBO 733, CRV 780) and 776 were not 
receiving DIG (PBO 400, CRV 376) at the time of randomization. Results: Shown below 
are 1-year Kaplan-Meier rates and Cox model (CRV:PBO) hazard ratios. 
All-Cause Mortality Death or HF Hospitalization 
Digitalis No Digitalis Digitalis No Digitalis 
Placebo 19.6% 16.1% 39.8% 33.8% 
Carvedilol 12.8% 8.0% 26.7% 23.1% 
Hazard ratio 0.71 0.48 0.71 0.64 
(95% CI) (0.55-0.91) (0.30-0.77) (0.59-0.85) (0.47-0.87) 
The effects of CRV on all-cause mortality and on death or HF hospitalization in patients 
not receiving DIG were at least as large as in those receiving DIG (interaction P values 
for DIG vs non-DIG were not significant). The rate of permanent withdrawal was lower 
with CRV than PBO and was similar in DIG and no-DIG patients (interaction P=0.25). 
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DIG did not increase the dsk of bradycardia attributable to CRV. 
Conclusions. These results indicate that DIG is not required for the efficacy or safety of 
CRV in severe chronic HF. Since CRV (but not DIG) reduces mortality, these data sup- 
port the use of CRV before DIG in HI=. 
1134-149 Endogenous  Ouaba in -L lke  Factor Predicts Progression 
Toward Heart Fai lure in Pat ients  With Id lopeth l¢ Di lated 
Card iomyopethy  
Maria V. Pitzalis, Paolo Manunta, Messimo lacoviello, Elisabetta Messaggio, Cinzia 
Fodeo, Roberta Romito, Viviana De Luce, Giuseppe Bianchi, Paolo Rizzon, Elisabetta 
De Tommasi, Institute of Cardiology, Bari, Italy, Division of Nephrology, Dialysis and 
Hypertension, Milan, Italy. 
Background. Plasma levels of endogenous ouabain factor (OLF) have shown to be 
increased in patients with left ventdcular dysfunction. Since it increases pedpheral resis- 
tance, sympathetic activity and cytokine excretion, OLF could favour the progression 
towards heart failure. The aim of this study was to assess the prognostic role of OLF in a 
group of patients with idiopathic dilated cardiomyopathy (WHO criteda). 
Methods. Ejection fraction (EF; mean 37%±11%), and plasma OLF levels (rddioimmu- 
nasaay method, mean 263.4±135.1) were assessed in 114 consecutive patients (age 
51 ±15 years; 89 male; 33 in NYHA class I, 62 in II, 19 in III), while receiving optimal ther- 
apy. Heart failure progression was defined by the appearance of a worsening in clinical 
conditions leading to one of the following: sustained increase in conventional therapies, 
hospitalization, cardiac transplant, death. 
Results. After 13±5 months of follow-up, 9 patients had a sustained increase of conven- 
tional therapy, 14 a hospitalization for heart failure, 2 cardiac transplantat and 1 died after 
worsening of heart failure. The prognostic significance of age, EF, NYHA class and OLF, 
at univariate and multivariate Cox regression analysis is shown in the table. 
Conclusions. High OLF plasma levels are independent predictors of heart failure pro- 
9ression in idiopathic dilated cardiomyopathy patients. 
Vadable Univariata analysis Multivadate analysis 
RR (95% CI) p RR (95% CI) p 
Age 1.04 (1.01-1.08) 0.01 1.00 (0.96-1.04) NS 
NYHA class 6.21 (3.10-12.44) <0.0001 3.02 (1.24-7.34) 0.02 
LVEF 0.9 (0.86-0.94) <0.0001 0.93 (0.88-0.98) 0.01 
OLF 1.002 1.001-1.003) <0.0001 1.0015 (1.0003-1.003) 0.01 
1134-150 The Use of Beta-Blockers in a University Hospital Heart 
Function Clinic: Insights Into Dosing and Tolerance 
Puneeta Tandon, Finlay A. McAlister, Ross T. Tsuyuki, Marilou Hervas-Malo, Shane 
Kimber, Paul W. Armstrong, University of Alberta, Edmonton, Alberta, Canada. 
BACKGROUND: Although multiple trials have conclusively proven that beta-blockers are 
beneficial in CHF, they appear to be under-prescribed in actual practice. The reasons for 
this underuse are uncertain. 
METHODS: A retrospective analysis of the Heart Function Clinic database at the Univer- 
sit,/of Alberta Hospital, Edmonton, Canada for the years 1989 to 2000 (a cohort of 932 
patients with a diagnosis of CHF confirmed by a cardiologist, objective measurements of 
LVEF at baseline, and prospective collection of clinical, laboratory, and pharmacy data at 
all subsequent clinic visits). 
RESULTS: Mean age at baseline was 73 years, 55% were female, 76% had systolic dys- 
function, 69% had an isohemio etiology, mean LVEF was 33%, and 51% had NYHA class 
III or IV symptoms. Over this pedod of time, beta-blockers were prescdbed for 42% of 
patients: patients were less likely to be prescribed a beta-blocker if they were over the 
age of 75 years (p=O.004), had NYHA class III or IV symptoms (p<0.0001), had a diagno- 
sis of COPD (p=0.0004), or had a resting HR< 60 at baseline (p=0.02). Baseline LVEF 
and BP were not different between those presodbed and not prescdbed beta-blockers. In 
those prescribed beta-blockers, the mean maximum daily doses achieved during fol- 
Iowup were less than those achieved in clinical trials (25.9 mg for cervedilol, 52.6 mg for 
atanolol, 77.3 mg for metoprolol, and 143.4 mg for acebutolol). Mean time to achieve 
maximum dose was 12 months and 29% of patients had their dosage reduced after 
achieving their maximum dose: there were no significant differences in mean BP, HR, or 
recorded symptoms before beta blockers were prescribed and in followup visits after 
maximum doses were achieved. 
CONCLUSIONS: Beta-blockers were under-used and under-dosed in this patient popu- 
lation relative to the tdal evidence; while the under-use was partially accounted for by 
patient factors, the under-dosing did not appear to be related to BP, HR, or NYHA class 
(suggesting that unmeasured factors, such as patient complaints of fatigue, may have 
limited the up-titration of beta-blockers in these patients). Prospective data collection is 
needed to examine the reasons for failure to achieve target doses of beta-blockers in 
CHI£ 
1134-151 Inc idence of  Ang ioedema in SOLVD 
John B. Kostis, Alan C. Wilson, UMDNJ-Robert Wood Johnson Medical School, New 
Brunswick, New Jersey. 
Background: Angioedema (AE) is a well recognized adverse effect of treatment with 
ACE inhibitors. However, there is wide variation in the reported rate of AE occurrence. 
Methods: We used data from the Studies of Left Ventricular Dysfunction (SOLVD), a 
clinical trial compadng enalapril to placebo in patients with left ventdcular dysfunction. 
Participants (pts) were given single blind enalapdl 2.5 mg bid for 1 week followed by pla- 
cebo for 2 weeks dudng a run-in phase, then randomized to double blind placebo or enal- 
april titrated to 10 mg bid and followed for an mean of 40 months. Two different methods 
of ascertaining the occurrence of AE were used sequentially in SOLVD: in the first 3567 
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pts, AE was not specified in the follow-up forms, but could be written in the "other side 
effects" field (FormetA); in the remaining 3202 pts, the occurrence of AE was elicited by 
specific inquiry (Format B). 
Pamufts: Reports of AE were elicited more frequently when format B was used (0.05% 
for A [2 pts] vs. 0.12% for B[4 pts]) in the run-in period and also in the double-blind follow- 
up period (see table). The rate of occurrence of AE with enalapril was higher than with 
placebo early after initiation of therapy, but additional cases accumulated during follow- 
up so that the differences in AE between placebo and enalapril were attenuated with 
time. 
Frequency of AE Adverse Event Reports 
SOLVD Follow Up Exam Form Duration of Follow Up 
4 Months Trial End 
Question Format n Enalapril Placebo Enalapril Placebo 
A. Non-specific 3,567 7 2 8 7 
B. Specific 3.202 24 22 76 81 
Conclusion: When compared to a non-specific question, the reported rate of AE was 
about 10 times higher (p<0.001) when a specific question to elicit its occurrence was 
asked. 
1134-152 Does the Degree  of  In ter ference With the Renin- 
Angiotenain System Influence the Response to  B- 
B lockade  in Chronic Heart  Fa i lure?  Resul ts  o f  the 
COPERNICUS Study 
Paul Mohacsi. Henry Krum, Jean L. Rouleau, Michael B. Fowler, Hugo A. Katus, Andrew 
J. Coats, Michel Tenders, Ildiko Amann-Zalan, Ellen B. Roecker, Milton Packer, for the 
COPERNICUS Study Group, University Hospital Bern, Bern, Switzerland. 
Background. ~-blockers are generally prescribed to patients with heart failure (HF) 
already receiving drugs that interfere with the renin-angiotensin system (angiotensin con- 
verting enzyme inhibitors [ACEI] and angiotsnsin receptor blockers [ARB]), but it is not 
clear if patients should be receiving low or high doses of ACEI or ARBs when they are ini- 
tiated on treatment with a B-blocker. 
Methods. We evaluated the effects of carvedilol (CRV) vs placebo (PBO) in 2289 patients 
with severe HF enrolled in the COPERNICUS study. At baseline, patients were receiving 
high, intermediate or low doses of an ACEI or ARB or neither drug. Dose groups were 
defined based on tertiles of observed doses in the trial. Hazard ratios (CRV:PBO) were 
calculated for each of the four subgroups for each of four outcome variables (see table). 
Results: 
Dose level of ACEI or ARB 
None Low Intermediate High 
(n=65) (n=673) (n=855) (n=686) 
All-cause mortality 0.51 0.63 0.65 0.70 
Death or HF hospitalization 0.77 0.72 0.68 0.69 
Death or cardiovascular hospitalization 0.70 0.78 0.76 0.67 
Death or any hospitalization 0.68 0.75 0.81 0.78 
CRV reduced the risk of a major clinical event to a similar degree in patients receiving 
low, intermediate or high doses of an ACEI or ARB or no ACEI/ARB at all (all interaction 
P=NS). Furthermore, CRV was well tolerated in all 4 subgroups. The rates of permanent 
withdrawal were lower with CRV vs PBO regardless of the dose level of ACEI or ARB. 
The dose of ACEI or ARB did not influence the frequency of adverse vasodilatory events. 
Conclusions. These results indicate that patients do not need to be receiving high doses 
of ACEI or ARB before being started on CRV and suggest that the degree of interference 
of the renin-angiotensin system does not influence the response to I]-blockade. 
1134-153 Ef fects  o f  Pentox i fy l l ine  in Severe Heart Failure 
Karen ~liwa. Angels Woodiwiss, Gavin Norton, Danielle Badenhorst, Athur Kibirigi, 
Daniel Skudicky, Carlos Libheber, Pinhas Sareli, Baragwanth Hospital, Johannesburg, 
South Africa, Physiology Depertment, University of Witwatersrand, Johannesburg, South 
Africa. 
Background: Patients with severe (NYHA FC IV) heart failure have a more than two-fold 
increase in cytokine concentrations in comparison to patients with moderate heart failure. 
Whether Pentoxifylline ( a drug known to inhibit the production of TNF-(:( ) modifies the 
marked changes in cytokines that occur in severe heart failure has to be determined. 
Methods: In a prospective, randomised, double blind, placebo controlled study we 
enrolled 18 consecutive patients with idiopathic dilated cardiomyopathy in FC IV. All 
patients required admission to intensive care unit for at least 7 days and intravenous ino- 
tropic support. Patients were randomised to Pentoxifylline (400 mg TDS) or Placebo in 
addition to diuretics, digoxin and ACE-inhibitors. Echocardiograms, radionuclide studies, 
Tumor necrosis factor-c~ (TNF-(x in pg/ml) and Fas/Apo-1 (an apoptosis signalling recep- 
tor) plasma concentrations were determined on admission and after 1 month of treat- 
ment. 
Results: There were no differences in baseline characteristics between the 2 study 
groups. Baseline ejection fraction of the study population was 16.8~-8%, and baseline 
plasma levels of TNF-(~ and Fas/Apo-1 were 19-+12pg/ml and 17_+8U/ml. These levels 
were significantly higher compared to the concentrations we found previously in patients 
in FC II-Ill (p<O.001 for both). After one month 3 patients died (2 in the placebo group). 
There was a significant reduction in the TNF-c~ (16.7_+3 to 8.0 _+2 pg/ml, p=<0.05) and 
Fas/Apo-t (15.2_+1 to 9.6_+2 U/ml, P=<0.05) plasma levels in the patients treated with 
Pentoxifylline with no significant changes in the Placebo group. This was associated with 
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a significant increase in ejection fraction in the Pentoxifylline group (16.6+8 to 24+4%, p< 
0.05). 
Conclusion: In patients with severe heart failure requiring inotropic support, treatment 
with Pentoxifylline is associated with a decrease in TNF-~ and Fas/Apo-1 plasma levels 
and improvement in systolic performance compared to Placebo. However, higher dose of 
Pentoxifylline may be required to fully suppress the TNF-c~ and Fas/Apo-I plasma levels. 
1134-154 RITZ 5: Randomized Intravenous "reZoeentan (an 
Endothelin ET-A/B Antagonist) for the Treatment of 
Pulmonary Edema: A Prospective Multlcenter Double 
Blind Placebo Controlled Study 
Edo Kaluski, Reuven Tzimilehman, Alon Marmur, Oscar Krakov, Olga Milovanov, Avi 
Caspi, Zvi Vemd, Gad Cotter, Assaf.harofeh Medical Center, Zerifin, Israel, Wo/fson 
Medical Center, Holon, Israel. 
Vasodilators are known to be efficacious in the treatment of acute congestive heart fail- 
ure (CHF). Therefore, we investigated the effect of Tezosentsn (a endothelin antagonist) 
in the treatment of pulmonary edema. 
Patient~ and Methods: Pulmonary edema was defined as acute CHF leading to respira- 
tory failure as evident by severe signs of pulmonary congestion and oxygen saturation < 
90% by pulse oxymeter despite oxygen treatment. Patients where recruited by mobile 
intensive care units, in the emergency room and during admission. All patients received 
oxygen by face mask, IV morphine 3 rng, IV furosemide 80 mg and IV isosorbide-dini- 
trate 1-3 mg/hour according to blood pressure. Thereafter, patients where randomized to 
receive placebo or Tezosentan 50 mg/hour which coutd have been up-titrated up to 100 
mg/hour. 
Results: 84 patients where randomized. Baseline characteristics where similar in the 
Tezosentsn group (n=42) and Placebo group (n=42). The primary endpoint; increase of 
oxygen saturation at 1 hour, was 7.8±5% in the placebo arm vs. 6±6.5% in the tezosen- 
tan group (n=NS). The secondary endpcint; rate of death, recurrent pulmonary edema 
and myocardial infarction was 19% in both groups 
In the Placebo group, echocardiographic EF (<50%), reduced baseline oxygen saturation 
(<85%) and low baseline mean arterial blood pressure (MAP) (<150 mmHg) were corre- 
lated to worse outcome. We found a significant correlation between treatment effect and 
outcome. In patients in whom MAP reduction by treatment at 15-~) minutes was 10-30% 
the recovery was faster as compared to those who had no reduction in MAP dunng treat- 
ment (<10%) or excessive MAP reduction (>30%). 
In a post-hoc analysis we have found that patients who received only 50 rag/hour 
tezosentan had better improvement han patients in the placebo group, while patients 
receiving 100 rag/hour fared worst. 
Conclusion: The outcome of pulmonary edema is determined by baseline MAP, oxygen 
saturation, the presence of systolic CHF and appropriate vasodilation (MAP reduction) in 
response to treatment. In the present study Tezosentan (an Endothelin antagonist) did 
not affect the outcome of pulmonary edema, possibly due to the high dose used. 
1134-155 Assoc ia t ion  o f  Qua l i ty  of  L i fe With Improved  Cl in ica l  
Outcomes: Results From the Valsartan Heart Failure 
Trial 
Luioi Tavazzi. Iloana Pins, YannTong Chiang, Robert Glazer, Nora Aknay, Jay Cohn, 
/RCCS Po/ic/inico S. Matteo, Pavia, Italy. 
Background: Improving the quality of life (QOL) for patients with chronic conditions and 
poor short-term survival such as heart failure (HF) is a common goal in new drug devel- 
opment. The aim of this post.hoc analysis was to examine the relationship between QOL, 
using Minnesota Living With Heart Failure (MLWHF) Questionnaire, and morbidity and 
mortality in the Valsertan Heart Failure Trial (VaI-HeFT). 
Methods: VaI-HeFT, a double blind randomized multicountry trial compared the effect of 
valsartan, a selective angiotensin II-receptor blocker, with placebo, in 5010 chronic HF 
patients (NYHA class II-IV), when added to prescribed treatment for HIE The primary 
endpoints of the study were mortality and morbidity (death, sudden death with resuscita- 
tion, iv therapy for HF, and hospitalization for HF). QOL was assessed by the MLWHF 
questionnaire as a secondary variable at months 1,4, 6, and every 3 months thereafter. 
Assessments were made in countries where the MLWHF Questionnaire were validated in 
the local languages: US, Itaty, Australia and the UK. The MLWHF score was analyzed 
using ANCOVA. A lower score indicates improved QOL. 
Results: In the overall VaI-HeFT population, valcartan significantly reduced risk of mor- 
bidity by 13.2% (p= 0.009). Total sample size for the QOL analysis was 3010. The valsar- 
tan group had significantly improved overall MLWHF scores compared to placebo at 
Endpoint (p<0.05). Higher MLWHF scores at baseline, Months 4, 12, and Endpoint were 
all associated (regardless of study treatment) with a higher risk of morbid events [4 th 
quartile (Q4) versus 1 st quartile (Q1); p<0.0001]. At baseline, comparisons of higher 
quartiles versus Q1 showed increasing risk of morbidity with increasing quartiles (Q2 RR 
= 1.28, Q3 RR = 1.38, Q4 RR = 1.68; p<0.01). Similar associations were observed 
between MLWHF score and mortality. 
Conclusions: Worsening QOL as measured by MLWHF questionnaire is associated 
with increased risk of morbidity and mortality. Valsartan treatment has a significant bene- 
ficial effect on QOL compared with placebo, when added to prescribed HF therapy. 
